ImmunoGen Message Board - Msg: 31243973

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen

IMGN 31.23

0.0%

Feb 26 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Gary Mohilner	8/30/2017 9:31:17 PM
	Read Replies (1) of 5665

Just wanted to see if their is any life here, their certainly is with IMGN. I believe the Jazz partnership makes all the questions finance through the Phase 3 trial for IMGN 853 moat. Leerink upgraded their target from $11 to $18 as I remember it, and this is cobmpletely in line with my belief that IMGN will end the year in double digits, and hopefully above the roughly $13 which it closed at at the end of 2015. I believe in time IMGN's market cap will more closely approach that of SGEN, and if their drug is approved before SGEN has another success, it could exceed that of SGEN. Gary

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next